1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsMicrobiome Function in Atopic Dermatitis (U01) is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). This opportunity supports mission-aligned projects and measurable outcomes.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Microbiome Function in Atopic Dermatitis Project Number 5U01AI152038-05 Contact PI/Project Leader GALLO, RICHARD L Summary/Abstract Atopic dermatitis (AD) is a common inflammatory skin disease. Recent observations strongly suggest that the abnormal microbiome present on the skin of subjects with AD is a major factor that influences the severity and chronic nature of this disorder.
In particular, Staphylococcus aureus promotes epidermal barrier dysfunction and exacerbates the local and systemic immune response. In healthy subjects, beneficial members of the skin microbiome act to limit the growth of Staphylococcus aureus but these beneficial bacterial strains are missing on adults with AD.
This project seeks to understand why adults with AD lack beneficial bacterial strains by study of the survival of a prototype strain of Staphylococcus hominis on AD skin. Interventions to improve its survival will be tested, and application in the pediatric AD population will be evaluated.
Overall, successful completion of the proposed aims of this ADRN Clinical Research Center will advance understanding of AD and provide essential information to permit development of an innovative new therapeutic approach based on targeted microbiome therapy. Public Health Relevance Statement Narrative This project seeks to establish an ADRN Clinical Research Center that will advance understanding of Atopic Dermatitis.
The successful completion of our aims will provide essential new information to permit development of an innovative therapy based on the topical use of naturally occurring beneficial skin bacteria.
Clinical Research Clinical Trials and Supportive Activities Eczema / Atopic Dermatitis Immunotherapy Infectious Diseases Microbiome Pediatric 18 year old 6 year old Adult Age Anti-Inflammatory Agents Antibiotic Resistance Antibiotics Antigen-Presenting Cells Atopic Dermatitis Bacteria Cells Characteristics Child Childhood Chronic Chronic Disease Clinical Research Cutaneous Defect Dermal Dermis Development Disease Dose Elements Environment Epithelial Cells Frequencies Functional disorder Goals Growth Human Immune Targeting Immune response Immune system Immunosuppression Immunosuppressive Agents Immunotherapy Incidence Inflammation Inflammatory Innovative Therapy Interruption Intervention Lymphocyte Measures Microbe Mission Mupirocin Myelogenous Nature Oral Patients Penetration Peptide Hydrolases Peptides Phenotype Play Population Recurrence Research Severities Shapes Skin Staphylococcus aureus Staphylococcus hominis Surface Testing Topical Antibiotic Topical application Toxin Triamcinolone Work antimicrobial beneficial microorganism cohort dysbiosis fighting improved innovation insight keratinocyte mast cell member microbial microbiome microbiome therapeutics novel therapeutic intervention pediatric patients prototype response side effect skin barrier skin disorder skin microbiome success UNIVERSITY OF CALIFORNIA, SAN DIEGO Administering Institutes or Centers National Institute of Allergy and Infectious Diseases Assistance Listing Number Project Funding Information for 2024 NIH Categorical SpendingClick here for more information on NIH Categorical Spending No Sub Projects information available for 5U01AI152038-05 Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding.
This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5U01AI152038-05 No Patents information available for 5U01AI152038-05 The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5U01AI152038-05 No Clinical Studies information available for 5U01AI152038-05 No news release information available for 5U01AI152038-05 No Historical information available for 5U01AI152038-05 No Similar Projects information available for 5U01AI152038-05 ## Select options for export:
According to the current listing, eligibility includes: Researchers and institutions focused on atopic dermatitis and skin microbiome research. Confirm the full requirements in the official notice before applying.
The current listing shows varies (example project number 5U01AI152038-07). Verify award ceilings, matching requirements, and allowable costs in the official notice.
Microbiome Function in Atopic Dermatitis (U01) is funded by National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
National Institute of Allergy and Infectious Diseases (NIAID) Resource-Related Research Projects (R24 Clinical Trial Not Allowed) is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). This grant supports resource development projects to advance infectious disease and immunology research. It focuses on developing and enhancing resources that facilitate research in these critical areas.
National Institute of Allergy and Infectious Diseases (NIAID) Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required) is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). This funding opportunity supports investigator-initiated clinical trials requiring enhanced oversight, with durations up to 7 years. While focused on clinical trials, modeling can be a critical component of trial design and analysis in infectious diseases and immunology.
The memorandum of agreement was signed August 4 and 5, disclosed by House appropriators on September 3, and runs through 2036. It names no dollar figure. Here is what is actually established, what is still speculation, and what researchers holding or planning NIAID biodefense awards should do before September 30.
Read articlePAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read articlePA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read article